[ad_1]
Ajinomoto has agreed to purchase Forge Biologics, a viral vector and plasmid contract development and manufacturing organization, for $620 million. “Forge brings to Ajinomoto an entirely new capability that will vitally enhance our Bio-Pharma Services business,” Yasuyuki Otake, general manager of Ajinomoto’s biopharmaceutical services business, says in a statement. Forge has a 18,580 m2 facility in Columbus, Ohio, called the Hearth. Forge, with approximately 300 employees, will operate as a subsidiary of Ajinomoto.
[ad_2]
Source link
